本文選題：急性早幼粒白血病　切入點(diǎn)：全反式維甲酸　出處：《中國實(shí)驗(yàn)血液學(xué)雜志》2017年02期 　論文類型：期刊論文

【摘要】：目的:探討全反式維甲酸(all-transretinoic acid,ATRA)聯(lián)合亞砷酸(arsenious acid,ATO)雙誘導(dǎo)治療急性早幼粒細(xì)胞白血病(acute promyelocytic leukemia,APL)的緩解率和伊達(dá)比星、全反式維甲酸、亞砷酸/復(fù)方黃黛片分層序貫鞏固治療的療效。方法:收集2010年至2016年接受雙誘導(dǎo)方案患者22例,分析雙誘導(dǎo)的CR率、早期死亡率、并發(fā)癥發(fā)生率和獲得完全緩解的時(shí)間長短。完全緩解后低、中�；颊呓邮�1-2個(gè)療程IDA單藥化療,ATRA和復(fù)方黃黛片/ATO交替治療4個(gè)周期;高�；颊呓邮躀A化療4療程,ATRA和復(fù)方黃黛片/ATO交替治療共4個(gè)周期。結(jié)果:雙誘導(dǎo)完全緩解率100%,誘導(dǎo)治療平均時(shí)間28.23±1.6 d,誘導(dǎo)期間50%發(fā)生感染,36.4%出現(xiàn)分化綜合征,27.3%有不同部位出血。完全緩解后分層鞏固治療組5年總生存率100%,無復(fù)發(fā)生存95.4%;結(jié)論:APL患者接受ATRA和ATO雙誘導(dǎo)治療能夠達(dá)到較高緩解率,誘導(dǎo)緩解時(shí)間短,并發(fā)癥可控。采用IDA、ATRA和ATO分層序貫治療作為緩解后鞏固方案,能夠降低復(fù)發(fā)率,延長患者的生存期,獲得極高的治愈率。
[Abstract]:Objective: to investigate the remission rate of all-trans retinoic acid (ATRAA) combined with arsenious acido (ATO) in the treatment of acute promyelocytic leukemia (AHL), and to evaluate the efficacy of ATRA-ATRA-ATRA-ATRA-ATRA-ATRA-ATO in the treatment of acute promyelocytic leukemia (AAPL) and in the treatment of acute promyelocytic leukemia (AHL). Methods: from 2010 to 2016, 22 patients who received double induction regimen were collected, and the rate of CR and early mortality were analyzed. The incidence of complications and the duration of complete remission were low after complete remission. Patients at moderate risk received 1-2 courses of IDA single drug chemotherapy and compound Huangdai tablets / ATO alternately for 4 cycles. Results: the complete remission rate of double induction was 100, the average time of induction treatment was 28.23 鹵1.6 days, and the incidence of infection during induction was 36.4% and differentiation syndrome was 27.3%. After complete remission, the 5-year overall survival rate was 100%, and the survival rate was 95.4%. Conclusion both ATRA and ATO can achieve a higher remission rate in patients with ATRA and ATO. The induction and remission time is short and the complications are controllable. The treatment of IDAA-ATRA and ATO can reduce the recurrence rate prolong the survival time and obtain a very high cure rate.
【作者單位】： 解放軍總醫(yī)院血液科;
【分類號】：R733.71

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李衛(wèi)華;何慧清;牛曉敏;;單藥伊達(dá)比星鞏固治療急性早幼粒細(xì)胞白血病的療效[J];實(shí)用醫(yī)學(xué)雜志;2014年14期

2 沈潔;;伊達(dá)比星在初治急性淋巴細(xì)胞白血病高危組患兒聯(lián)合化療中的使用和療效觀察[J];中國醫(yī)學(xué)創(chuàng)新;2013年20期

3 張志峰,齊社寧;伊達(dá)比星與腫瘤細(xì)胞凋亡[J];現(xiàn)代腫瘤醫(yī)學(xué);2004年05期

4 張燕香，，沈志祥，李秀松，陳鈺，張芬琴;伊達(dá)比星治療20例白血病的療效觀察[J];新醫(yī)學(xué);1996年08期

5 王秀菊,尹松梅,馬麗平,謝雙峰,聶大年;急性嗜酸粒細(xì)胞白血病1例報(bào)告[J];新醫(yī)學(xué);2005年06期

6 陳婷;張誠;張曦;高蕾;高力;羅曉慶;劉煥鳳;;伊達(dá)比星為預(yù)處理方案的自體造血干細(xì)胞移植治療急性淋巴細(xì)胞白血病的臨床研究[J];西部醫(yī)學(xué);2012年11期

7 趙肖霞;伊達(dá)比星阿糖胞苷聯(lián)合治療非淋巴細(xì)胞白血病16例[J];醫(yī)藥導(dǎo)報(bào);1999年06期

8 崔釗;氟達(dá)拉濱、阿糖胞苷、粒細(xì)胞刺激因子、伊達(dá)比星治療高危型MDS和AML[J];國外醫(yī)學(xué).輸血及血液學(xué)分冊;1998年06期

9 M.Flasshove,P.Meusers,J.Schütte,R.Noppeney,D.W.Beelen,S.Sohrab,U.Roggenbuck,G.Kemmeries,G.Brittinger,S.Seeber,M.E.Scheulen,傅暉;運(yùn)用去甲氧基柔紅霉素(伊達(dá)比星)和阿糖胞苷誘導(dǎo)療法治療復(fù)發(fā)性急性粒細(xì)胞白血病的長期存活觀察[J];The Chinese-German Journal of Clinical Oncology;2001年06期

10 ;[J];;年期

相關(guān)會(huì)議論文 前1條

1 阮國瑞;趙紅珊;常艷;李金蘭;秦亞溱;陳珊珊;黃曉軍;;PDCD5基因轉(zhuǎn)移促進(jìn)伊達(dá)比星在裸鼠體內(nèi)及體外的抑瘤作用[A];第七屆全國血液免疫學(xué)學(xué)術(shù)大會(huì)暨2008年浙江省血液病學(xué)術(shù)年會(huì)論文匯編[C];2008年

本文編號：1636084